Biochemotherapy in patients with advanced head and neck mucosal melanoma

Head and Neck

Volumn 30, Issue 12, 2008, Pages 1592-1598

  Bartell, Holly L ^a   Bedikian, Agop Y ^b   Papadopoulos, Nicholas E ^b   Dett, Tina K ^b   Ballo, Matthew T ^b   Myers, Jeffrey N ^b   Hwu, Patrick ^b   Kim, Kevin B ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biochemotherapy; Head and neck; Melanoma; Mucosal; Systemic therapy

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALE; MELANOMA; MUCOSAL MELANOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; INTERFERON-ALPHA; INTERLEUKIN-2; MALE; MEDICAL RECORDS; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 57349126400     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20910     Document Type: Article

References (31)

1. Gutman M, Inbar M, Chaitchik S, et al. Malignant melanoma of the mucous membranes. Eur J Surg Oncol 1992;18:307-312.
2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-1678.
3. Loree TR, Mullins AP, Spellman J, North JH Jr, Hicks WL Jr. Head and neck mucosal melanoma: a 32-year review. Ear Nose Throat J 1999;78:372-375.
4. Conley J, Pack GT. Melanoma of the mucous membranes of the head and neck. Arch Otolaryngol 1974;99:315-319.
5. Temam S, Mamelle G, Marandas P, et al. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 2005;103:313-319.
6. Patel SG, Prasad ML, Escrig M, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002;24:247-257.
7. Guzzo M, Grandi C, Licitra L, Podrecca S, Cascinelli N, Molinari R. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. Eur J Surg Oncol 1993;19:316-319.
8. Stern SJ, Guillamondegui OM. Mucosal melanoma of the head and neck. Head Neck 1991;13:22-27.
9. Yii NW, Eisen T, Nicolson M, et al. Mucosal malignant melanoma of the head and neck: the Marsden experience over half a century. Clin Oncol (R Coll Radiol) 2003;15:199-204.
10. Lengyel E, Gilde K, Remenar E, Esik O. Malignant mucosal melanoma of the head and neck. Pathol Oncol Res 2003;9:7-12.
11. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-4346.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
13. Goydos JS, Mann B, Kim HJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005;200:362-370.
14. Gilligan D, Slevin NJ. Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses. Br J Radiol 1991;64:1147-1150.
15. Chaudhry AP, Hampel A, Gorlin RJ. Primary malignant melanoma of the oral cavity: a review of 105 cases. Cancer 1958;11:923-928.
16. Freedman HM, DeSanto LW, Devine KD, Weiland LH. Malignant melanoma of the nasal cavity and paranasal sinuses. Arch Otolaryngol 1973;97:322-325.
17. Lund VJ, Howard DJ, Harding L, Wei WI. Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope 1999;109 (Part 1):208-211.
18. Pandey M, Mathew A, Iype EM, Sebastian P, Abraham EK, Nair KM. Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature. Eur J Cancer Prev 2002;11:3-10.
19. Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg 1977;134:531-535.
20. Shibuya H, Takeda M, Matsumoto S, Hoshina M, Suzuki S, Takagi M. The efficacy of radiation therapy for a malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys 1993;25:35-39.
21. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-a. Ann Oncol 1996;7:827-835.
22. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998;16:2921-2929.
23. Flaherty LE, Robinson W, Redman BG, et al. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. Cancer 1993;71:3520-3525.
24. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-2052.
25. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-a after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995;31A:876-881.
26. O'Day SJ, Gammon G, Boasberg PD, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-2761.
27. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon a-2b. J Clin Oncol 1999;17:968-975.
28. Atkins MB, Lee S, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon α-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol 2003;22:708a (abstract no. 2847).
29. Del Vecchio M, Bajetta E, Vitali M, et al. Multicenter phase III randomized trial of cisplatin, vindesine and dacarbazine (CVD) versus CVD plus subcutaneous (sc) interleukin-2 (IL-2) and interferon-α-2b (IFN) in metastatic melanoma patients (pts). Proc Am Soc Clin Oncol 2003;709 (abstract no. 2849).
30. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:5426-5434.
31. Bedikian AY, Johnson MM, Broemeling LD, et al. Prognostic factors determining long term survival of patients with unresectable stage III and stage IV metastatic melanoma (MM) treated with combination therapy or IL-2 based biochemotherapy (BCC). Proc Am Soc Clin Oncol 2005 (abstract no. 7544).